×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RCUS – arcus biosciences, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RCUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/26
04:05 pm
rcus
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Medium
Report
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
2/25
11:26 pm
rcus
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/25
07:26 pm
rcus
Arcus (RCUS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arcus (RCUS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
04:27 pm
rcus
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update [Yahoo! Finance]
Medium
Report
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update [Yahoo! Finance]
2/25
04:05 pm
rcus
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
Medium
Report
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
2/23
05:00 pm
rcus
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
Medium
Report
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
2/15
11:53 pm
rcus
A Look At Arcus Biosciences (RCUS) Valuation After Wells Fargo Downgrade And Shifting Analyst Sentiment [Yahoo! Finance]
Low
Report
A Look At Arcus Biosciences (RCUS) Valuation After Wells Fargo Downgrade And Shifting Analyst Sentiment [Yahoo! Finance]
2/13
06:29 am
rcus
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at Wells Fargo & Company from a "strong-buy" rating to a "hold" rating.
Medium
Report
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at Wells Fargo & Company from a "strong-buy" rating to a "hold" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/25
04:40 pm
rcus
Form S-3ASR Arcus Biosciences, Inc.
Medium
Report
Form S-3ASR Arcus Biosciences, Inc.
2/25
04:20 pm
rcus
Form S-8 Arcus Biosciences, Inc.
Medium
Report
Form S-8 Arcus Biosciences, Inc.
2/25
04:12 pm
rcus
Form 10-K Arcus Biosciences, Inc. For: Dec 31
Medium
Report
Form 10-K Arcus Biosciences, Inc. For: Dec 31
2/25
04:08 pm
rcus
Form 8-K Arcus Biosciences, Inc. For: Feb 25
Medium
Report
Form 8-K Arcus Biosciences, Inc. For: Feb 25
1/26
08:22 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: ROSEN TERRY J
Low
Report
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: ROSEN TERRY J
1/26
08:22 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Tang Carolyn C.
Low
Report
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Tang Carolyn C.
1/26
08:22 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Markus Richard
Low
Report
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Markus Richard
1/26
08:22 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Jaen Juan C.
Low
Report
Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Jaen Juan C.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/26
Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Mizuho. They set a "buy" rating on the stock.
15.6%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
TOP News Decliners
3/14
Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
-24.3%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: